<DOC>
	<DOCNO>NCT02289898</DOCNO>
	<brief_summary>This randomize , double blind , 3 arm ( 1:1:1 ) study subject 1st-line metastatic pancreatic ductal adenocarcinoma . The purpose test efficacy safety demcizumab , give combination gemcitabine Abraxane® compare placebo . The administration gemcitabine Abraxane® standard treatment patient metastatic pancreatic ductal adenocarcinoma .</brief_summary>
	<brief_title>Study Gemcitabine , Abraxane® Plus Placebo Versus Gemcitabine , Abraxane® Plus 1 2 Truncated Courses Demcizumab Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>1 . Subjects must histologically confirm metastatic pancreatic ductal adenocarcinoma.. Prior chemotherapy and/or radiotherapy either adjuvant neoadjuvant set metastatic disease allow . 2 . Availability FFPE tumor tissue ( either primary tumor , locoregional disease metastatic site ) , either fresh coreneedlebiopsied archive ( two FFPE core prefer whenever possible ) . If fresh tissue obtain , core biopsy must do least 7 day prior randomization . 3 . Age ≥21 year 4 . ECOG performance status 0 1 5 . Measurable disease per RECIST v1.1 5 . Adequate organ marrow function 6 . Signed Informed Consent Form 7 . For woman childbearing potential , agreement use two effective form contraception 1 . Subjects neuroendocrine tumor pancreas , acinar tumor pancreas pancreatic tumor mixed histology . 2 . Subjects receive heparin , warfarin , factor Xa inhibitor similar anticoagulant . Note : Subjects may receive lowdose aspirin and/or nonsteroidal antiinflammatory agent . 3 . Subjects brain metastasis , leptomeningeal disease , uncontrolled seizure disorder , active neurologic disease 4 . Subjects Grade &gt; 2 peripheral neuropathy 5 . Subjects clinically significant ascites 6 . Malignancies pancreatic cancer successfully treat within 3 year prior randomization , except adequately treat carcinoma situ cervix , basal squamous cell skin cancer , treat superficial bladder cancer , localize prostate cancer treat surgically curative intent , ductal carcinoma situ treat surgically curative intent 7 . Significant intercurrent illness limit patient 's ability participate study may result death next 18 month 8 . History significant allergic reaction attribute humanized human monoclonal antibody therapy 9 . Subjects know clinically significant gastrointestinal disease include , limited , inflammatory bowel disease 10 . Pregnant woman nurse woman 11 . Subjects know HIV infection 12 . Known bleed disorder coagulopathy</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>1st-line metastatic pancreatic ductal adenocarcinoma</keyword>
</DOC>